Dianthus Therapeutics to Participate in The TD Cowen 46th Annual Health Care Conference
Rhea-AI Summary
Dianthus Therapeutics (Nasdaq: DNTH) will participate in the TD Cowen 46th Annual Health Care Conference in Boston. Marino Garcia, CEO, will join an analyst-led fireside chat on March 3, 2026 at 1:50 pm ET and hold one-on-one investor meetings.
A webcast will be available under News and Events in the Investors section of the company's website.
Positive
- None.
Negative
- None.
News Market Reaction – DNTH
In the Feb 24 session, DNTH gained 0.34%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 05 | Conference participation | Neutral | -3.2% | Announcement of Guggenheim biotech summit fireside chat and investor meetings. |
| Jan 05 | Conference participation | Neutral | -7.0% | J.P. Morgan Healthcare Conference presentation and one-on-one investor meetings. |
| Dec 23 | Clinical trial start | Positive | -2.6% | Initiation of Phase 1 trial for LBL-047 (DNTH212) in SLE and volunteers. |
| Nov 24 | Conference participation | Neutral | +5.4% | Evercore healthcare conference fireside chat and investor meetings. |
| Nov 05 | Earnings and updates | Positive | +1.6% | Q3 2025 results with positive clinical progress and strengthened cash position. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
DNTH’s stock has often reacted modestly or negatively around conference and clinical updates, while earnings and some conference appearances have produced positive moves. The current strength on another conference participation notice contrasts with past mixed reactions, especially to clinical progress news.
Over the past few months, DNTH has highlighted multiple investor events and pipeline milestones. Conference participation announcements on Nov 24, 2025 and Jan 5, 2026 produced mixed one-day moves, while a Phase 1 trial initiation for DNTH212 on Dec 23, 2025 saw a -2.65% reaction despite its strategic importance. Q3 2025 results on Nov 5, 2025 emphasized positive clinical progress and an estimated cash position of about $525M, with the stock up 1.6%. Today’s conference news fits the pattern of frequent investor-relations outreach.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK and WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the Company’s participation in the TD Cowen 46th Annual Health Care Conference in Boston. Marino Garcia, CEO of Dianthus Therapeutics, will participate in an analyst-led fireside chat on Tuesday, March 3, 2026 at 1:50 pm EST and will host one-on-one meetings with investors.
A webcast of this presentation may be accessed under “News and Events” in the Investors section of the Dianthus Therapeutics website.
About Dianthus Therapeutics
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who aim to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.
To learn more, please visit www.dianthustx.com and follow us on LinkedIn.
Contact
Jennifer Davis Ruff
Dianthus Therapeutics
jdavisruff@dianthustx.com
